Skip to content
  • KOSPI 3236.86 +4.33 +0.13%
  • KOSDAQ 1035.68 -10.87 -1.04%
  • KOSPI200 429.15 +0.93 +0.22%
  • USD/KRW 1150.2 -3.00 -0.26%
  • JPY100/KRW 1,047.68 2.78 0.27%
  • EUR/KRW 1,359.36 -1.70 -0.13%
  • CNH/KRW 177.6 -0.16 -0.09%
View Market Snapshot

COVID-19 treatment

Celltrion’s COVID-19 treatment reduces incidence of severity by 70%

Having proven efficacy on beta and gamma variants, Regkirona will continue animal testing for efficacy on delta variant

By Jul 13, 2021 (Gmt+09:00)

Dr. Oana Sandulescu presents Celltrion Regkirona’s global phase III clinical trial results at ECCMID.
Dr. Oana Sandulescu presents Celltrion Regkirona’s global phase III clinical trial results at ECCMID.

Celltrion Inc. on July 13 said that its COVID-19 treatment Regkirona has proven effective in reducing the incidence of severe cases of the virus by 70% in all patients.

The biopharmaceutical company presented the results of Regkirona’s global phase III clinical trials at the 31st European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) held online July 9-12.

The presentation was based on its 28-day trial on a total of 1,315 mild and moderate COVID-19 cases. Compared to the placebo group, the patients that were treated with Regkirona showed 70% less incidence of severe cases.

Regkirona also decreased the incidence of severe cases among the high-risk group, such as those with underlying conditions, by 72%. The figure was only 54% in phase II trials.

Regkirona also reduced the time to clinical symptom improvement by 4.7 days compared to the placebo group. The figure was 4.9 days among the high-risk group of patients.

“We will accelerate the global approval of Regkirona based on our phase III clinical trial results,” said a Celltrion official.  

Celltrion added that it confirmed the efficacy of Regkirona in treating the beta and gamma variants of COVID-19 in June of this year through animal efficacy tests. The company will conduct more of such tests in July to test Regkirona’s efficacy in treating the delta variant.  

Write to Woo-sub Kim at duter@hankyung.com

Daniel Cho edited this article.

Comment 0

0/300